Panacea Life Sciences Holdings (Panacea Life Sciences Holdings) Sloan Ratio % : -34.73% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Panacea Life Sciences Holdings Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Panacea Life Sciences Holdings's Sloan Ratio for the quarter that ended in Mar. 2024 was -34.73%.

Warning Sign:

When sloan ratio (-35.73)% higher than 25% or lower than -25%, earnings are more likely to be made up of accruals.

As of Mar. 2024, Panacea Life Sciences Holdings has a Sloan Ratio of -34.73%, indicating earnings are more likely to be made up of accruals.

Panacea Life Sciences Holdings Sloan Ratio % Historical Data

The historical data trend for Panacea Life Sciences Holdings's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Panacea Life Sciences Holdings Sloan Ratio % Chart

Panacea Life Sciences Holdings Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Sloan Ratio %

17.52

-5.81

-33.59

-35.73

Panacea Life Sciences Holdings Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Sloan Ratio %	Get a 7-Day Free Trial											-30.57	-32.33	-28.38	-35.73	-34.73

Competitive Comparison of Panacea Life Sciences Holdings's Sloan Ratio %

For the Drug Manufacturers - Specialty & Generic subindustry, Panacea Life Sciences Holdings's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Panacea Life Sciences Holdings's Sloan Ratio % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Panacea Life Sciences Holdings's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Panacea Life Sciences Holdings's Sloan Ratio % falls into.

Panacea Life Sciences Holdings Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Panacea Life Sciences Holdings's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sloan Ratio	=	(Net Income (A: Dec. 2023 )	-	Cash Flow from Operations (A: Dec. 2023 )
	-	Cash Flow from Investing (A: Dec. 2023 ))	/	Total Assets (A: Dec. 2023 )
	=	(-8.015	-	-1.524
	-	-0.065)	/	17.983
	=	-35.73%

Panacea Life Sciences Holdings's Sloan Ratio for the quarter that ended in Mar. 2024 is calculated as

Sloan Ratio	=	(Net Income (TTM)	-	Cash Flow from Operations (TTM))
	-	Cash Flow from Investing (TTM))	/	Total Assets (Q: Mar. 2024 )
	=	(-7.67	-	-1.567
	-	-0.055)	/	17.413
	=	-34.73%

Panacea Life Sciences Holdings's Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was -1.864 (Jun. 2023 ) + -2.151 (Sep. 2023 ) + -2.209 (Dec. 2023 ) + -1.446 (Mar. 2024 ) = $-7.67 Mil.
Panacea Life Sciences Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 was -0.483 (Jun. 2023 ) + -0.729 (Sep. 2023 ) + 0.002 (Dec. 2023 ) + -0.357 (Mar. 2024 ) = $-1.57 Mil.
Panacea Life Sciences Holdings's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 was -0.009 (Jun. 2023 ) + -0.023 (Sep. 2023 ) + -0.018 (Dec. 2023 ) + -0.005 (Mar. 2024 ) = $-0.06 Mil.

Panacea Life Sciences Holdings (OTCPK:PLSH) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Mar. 2024, Panacea Life Sciences Holdings has a Sloan Ratio of -34.73%, indicating earnings are more likely to be made up of accruals.

Panacea Life Sciences Holdings Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Panacea Life Sciences Holdings's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.

Panacea Life Sciences Holdings (Panacea Life Sciences Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Panacea Life Sciences Holdings Inc (OTCPK:PLSH) » Definitions » Sloan Ratio %

Comparable Companies

Traded in Other Exchanges

N/A

Address

5910 S University Boulevard, C18-193, Greenwood Village, CO, USA, 80121

Website

https://www.panacealife.com

Panacea Life Sciences Holdings Inc is a cannabinoid nutraceutical manufacturer and research company that produces natural pharmaceutical alternatives for consumers and pets. It manufactures and sells soft gels, gummies, tinctures, sublingual tablets, cosmetics, and other topicals.

Executives

Leslie Buttorff	director, 10 percent owner, officer: CHIEF EXECUTIVE OFFICER	16194 W 45TH DRIVE, GOLDEN CO 80403
Janice Nerger	director	5910 S UNIVERSITY BLVD., C18-193, GREENWOOD VILLAGE CO 80121
Nathan Joel Berman	officer: CONTROLLER & PRIN ACTNG OFCR	16194 W 45TH DRIVE, GOLDEN CO 80403
22nd Century Group, Inc.	10 percent owner	8560 MAIN STREET, SUITE 4, WILLIAMSVILLE NY 14221
Harvey J Kesner	10 percent owner	65 E. 55TH STREET, NEW YORK NY 10022
Lawrence Wert	director	170 NUTTALL RD, RIVERSIDE IL 60546
Chesne Derek Du	officer: Chief Growth Officer	80 NE 4TH AVENUE, SUITE 28, DELRAY BEACH FL 33483
Alvaro Daniel Alberttis	director	80 NE 4TH AVENUE, SUITE 28, DELRAY BEACH FL 33483
Vladislav Yampolsky	director, 10 percent owner	332 PLAZA REAL, BOCA RATON FL 33432
Steven A Schwartz	director	332 PLAZA REAL, BOCA RATON FL 33432
Andrew L. Johnson	officer: Chief Strategy Officer	80 NE 4TH AVE. SUITE 28, DELRAY BEACH FL 33483
Emiliano Angel Aloi	officer: President	510 SUNSHINE DRIVE, DELRAY BEACH FL 33444
Jonathan Gilbert	director, officer: Executive Chairman	36 SYCAMORE LANE, ROSALYN HEIGHTS NY 11577
John C Price	director	4721 IRONTON STREET, BUILDING A, DENVER CO 80239
Kevin James Esval	director	NEURO HITECH INC, ONE PENN PLAZA STE 1503, NEW YORK NY 10019